The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents. They are useful in the treatment of cognitive impairment associated with neuro-degenarative disorders like attention deficient hyperactivity, Alzheimer's, Parkinson, Schizophrenia and Huntington's.
"We are very pleased by the issuance of these patents in these countries to Suven for our drug candidates that are being developed for CNS disorders which targets an $18 billion potential market opportunity globally" Venkat Jasti, chief executive officer of Suven, stated in a press release.
He said that the granted patents were exclusive intellectual property of Suven and were achieved through internal discovery research efforts. Products out of these inventories, which were in pre-clinical development, may be out-licensed at the stage of clinical phase-I or phase-II stage.
